MARKET

ACAD

ACAD

Acadia Pharmaceuticals Inc
NASDAQ
15.20
-0.34
-2.19%
After Hours: 15.27 +0.07 +0.46% 17:44 05/24 EDT
OPEN
15.75
PREV CLOSE
15.54
HIGH
15.83
LOW
15.19
VOLUME
1.52M
TURNOVER
0
52 WEEK HIGH
33.99
52 WEEK LOW
14.65
MARKET CAP
2.51B
P/E (TTM)
-1196.8504
1D
5D
1M
3M
1Y
5Y
After UnitedHealth Cyberattack, Drug Distributor Cencora Notifies Americans' Health Information Stolen In Data Breach In February
Drug wholesaler Cencora Inc, formerly AmerisourceBergen, is notifying affected individuals about a cyberattack earlier this year. The breached data includes patient names, postal addresses, dates of birth, and medication details. The company obtained patients’ data through partnerships with other drug makers.
Benzinga · 2d ago
Shareholders Will Probably Hold Off On Increasing ACADIA Pharmaceuticals Inc.'s (NASDAQ:ACAD) CEO Compensation For The Time Being
ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) to hold its Annual General Meeting on 29th of May. The company's three-year loss to shareholders was 27% while its EPS grew by 40% over the past three years. CEO Steve Davis' total compensation includes salary of US$ Total compensation is similar to the industry average for the same size company. ACADIA pharmaceuticals has seen its earnings per share grow by 56% in the past year.
Simply Wall St · 3d ago
Notable ETF Outflow Detected - LABU, FDMT, ETNB, ACAD
NASDAQ · 6d ago
Weekly Report: what happened at ACAD last week (0513-0517)?
Weekly Report · 6d ago
ACADIA PHARMACEUTICALS REPORTS INDUCEMENT GRANTS UNDER NASDAQ LISTING RULE 5635(C)(4)
Reuters · 05/17 20:05
ACADIA PHARMACEUTICALS ANNOUNCES LAUNCH OF MAGNOLIA'S GUIDE TO ADVENTURING: A GROUNDBREAKING DOCUMENTARY SERIES AIMING TO RAISE DISEASE AWARENESS AND REDEFINE PERCEPTIONS OF RETT SYNDROME
Reuters · 05/15 13:05
Weekly Report: what happened at ACAD last week (0506-0510)?
Weekly Report · 05/13 09:29
Analysts Offer Insights on Healthcare Companies: C4 Therapeutics (CCCC), ACADIA Pharmaceuticals (ACAD) and Disc Medicine (IRON)
TipRanks · 05/13 02:10
More
About ACAD
Acadia Pharmaceuticals Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases. It has a portfolio of commercial stage products, in-development product opportunities, and research programs that are designed to address unmet needs in CNS disorders and rare diseases. Its pipeline includes NUPLAZID (pimavanserin), DAYBUE (trofinetide), ACP-101, ACP-204, and Antisense Oligonucleotide (ASO) Programs. NUPLAZID is a selective serotonin inverse agonist/antagonist preferentially targeting the 5-HT2A receptor. NUPLAZID is developed for the treatment for Parkinson's Disease Psychosis. Trofinetide is a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 (IGF-1) designed to treat the core symptoms of Rett syndrome by reducing neuroinflammation and supporting synaptic function.

Webull offers ACADIA Pharmaceuticals Inc stock information, including NASDAQ: ACAD real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ACAD stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ACAD stock methods without spending real money on the virtual paper trading platform.